This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Redwood Pharma Beheer

Beheer criteriumcontroles 1/4

Redwood Pharma's CEO is MV Vidaeus, appointed in Jan 2012, has a tenure of 12.58 years. directly owns 0.93% of the company’s shares, worth SEK29.18K. The average tenure of the management team and the board of directors is 10.6 years and 0.8 years respectively.

Belangrijke informatie

MV Vidaeus

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	12.6yrs
Eigendom CEO	0.9%
Management gemiddelde ambtstermijn	10.6yrs
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

Is Redwood Pharma (NGM:REDW) In A Good Position To Invest In Growth?

Apr 09

CEO

MV Vidaeus (58 yo)

12.6yrs

Tenure

Mr. Martin Vidaeus, also known as MV, MBA, is the Founder of Redwood Pharma AB. Mr. Vidaeus holdss many year's experience in life science business development in the US and Europe. He has successful histor...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ulf Bjorklund	Chairman & Chief Medical Officer	less than a year	geen gegevens	0.062% SEK 1.9k
Martin Vidaeus	Founder	12.6yrs	geen gegevens	0.93% SEK 29.2k
Hans Ageland	Founder & COO	12.6yrs	geen gegevens	0.15% SEK 4.8k
Peter Rooslien	Chief Financial Officer	8.3yrs	geen gegevens	geen gegevens

10.6yrs

Gemiddelde duur

65.5yo

Gemiddelde leeftijd

Ervaren management: REDW's management team is seasoned and experienced (10.6 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ulf Bjorklund	Chairman & Chief Medical Officer	less than a year	geen gegevens	0.062% SEK 1.9k
Martin Vidaeus	Founder	12.6yrs	geen gegevens	0.93% SEK 29.2k
Tom Ronnlund	Independent Director	less than a year	geen gegevens	geen gegevens
Hakan Magnusson	Independent Director	less than a year	geen gegevens	geen gegevens

0.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: REDW's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

This company listing is no longer active

Redwood Pharma Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Redwood Pharma AB, Annual General Meeting, Jun 20, 2024

Less than half of directors are independent

Recent updates

Redwood Pharma AB, Annual General Meeting, Jun 20, 2024

Redwood Pharma AB (publ)'s Product RP501 attracted a lot of interest at ARVO in Seattle

New major risk - Revenue and earnings growth

Redwood Pharma AB (publ) Presents Positive Results from Clinical Study with RP501 Against Dry Eye

Redwood Pharma AB (Publ) Completes Further Preparations for the Scale-Up of Production of the Company's Medical Technology Product RP501

Less than half of directors are independent

Redwood Pharma Receives Approval from Austrian Federal Office for Safety in Health Care to Initiate Clinical Trial of RP501

Redwood Pharma Receives Approval from an Austrian Ethics Committee for Start of A Clinical Trial of RP501

Is Redwood Pharma (NGM:REDW) In A Good Position To Invest In Growth?

Redwood Pharma AB Announces Supplementary Analyses to Topline Phase Ii Results Reveal Additional RP101 Clinical Strengths

New 90-day low: kr6.46

New 90-day low: kr9.10

New 90-day low: kr9.20

New 90-day low: kr9.80

Redwood Pharma AB (publ) Officially Names the New Development Project for Treatment of Mild Dry Eye as RP501

New 90-day high: kr14.35

New 90-day high - kr14.25

New 90-day low - kr10.05

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd